Compass Therapeutics (NASDAQ:CMPX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Compass Therapeutics (NASDAQ:CMPX) from a sell rating to a hold rating in a research note issued to investors on Monday.

Several other brokerages also recently commented on CMPX. Cantor Fitzgerald assumed coverage on Compass Therapeutics in a research report on Wednesday, December 3rd. They issued an “overweight” rating on the stock. Raymond James Financial reaffirmed an “outperform” rating and set a $9.00 target price on shares of Compass Therapeutics in a research report on Tuesday, January 6th. Citizens Jmp set a $10.00 price target on shares of Compass Therapeutics in a report on Wednesday, December 3rd. Citigroup began coverage on shares of Compass Therapeutics in a report on Wednesday, December 3rd. They set an “outperform” rating on the stock. Finally, William Blair assumed coverage on shares of Compass Therapeutics in a research note on Monday, January 5th. They issued an “outperform” rating for the company. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Compass Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $13.36.

Compass Therapeutics Stock Performance

Shares of NASDAQ:CMPX opened at $6.47 on Monday. The stock’s 50-day moving average is $5.74 and its 200-day moving average is $4.57. The company has a market cap of $1.15 billion, a P/E ratio of -14.38 and a beta of 1.46. Compass Therapeutics has a 52-week low of $1.33 and a 52-week high of $6.88.

Institutional Investors Weigh In On Compass Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Flagship Harbor Advisors LLC acquired a new position in shares of Compass Therapeutics in the 4th quarter worth approximately $32,000. Russell Investments Group Ltd. grew its position in Compass Therapeutics by 3,933.7% in the third quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock valued at $27,000 after acquiring an additional 7,592 shares during the period. Apollon Wealth Management LLC acquired a new position in Compass Therapeutics during the third quarter worth $35,000. Xponance LLC bought a new position in shares of Compass Therapeutics during the fourth quarter valued at $55,000. Finally, CIBC Bancorp USA Inc. acquired a new stake in shares of Compass Therapeutics in the 3rd quarter valued at $37,000. 68.43% of the stock is owned by institutional investors and hedge funds.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.